Damien McDonald is the Chief Executive Officer of LivaNova.
Previously, Mr. McDonald served as Chief Operating Officer of LivaNova. Prior to that, he was Group Executive and Corporate Vice President at Danaher Corporation where he led a $1.5-billion group of dental consumables companies. Earlier in his tenure, he was Group President of Kerr where he and his team focused on building a strong research and development pipeline while improving operational performance utilizing the Danaher Business System. Additionally, Mr. McDonald previously led Zimmer’s spine division where he demonstrated his leadership skills, attracting a strong executive team that created a growth trajectory for the business unit. Earlier in his career, he worked with J&J’s Medical Device Franchises, including Ethicon, where he led marketing of the $2.5-billion medical device unit.
Mr. McDonald earned an MBA at the Institute for Management Development (IMD) in Lausanne, Switzerland, along with a Master of Science in International Economics from the University of Wales, U.K. He also holds a Bachelor of Economics degree and Bachelor of Pharmacy degree, both from the University of Queensland, Australia.
Mr. McDonald is a non-executive director of the regenerative medicine company Avita Medical (ASX:AVH).
Edward Andrle is General Manager, Neuromodulation at LivaNova.
Previously, Andrle served as Senior Vice President of New Ventures and Business Development for LivaNova, and was Vice President of Strategy and Business Development at Sorin Group for five years prior to that.
Andrle had a successful career in the medical device industry, where he also became an entrepreneur and a CEO of start-up companies like Teramed (endovascular stent-graft), Myocor (mitral valve surgery) and StarFire Medical (neurovascular technology).
Prior to this Andrle spent 5 years as a Vice President at Boston Scientific, where he led a new business unit focused on peripheral vascular catheters and guidewires that accounted for over $100 million in sales.
He holds an MBA from the Stanford Graduate School of Business and a BS in Chemical engineering from the University of Notre Dame.
Thad Huston is the Chief Financial Officer of LivaNova.
Huston joined LivaNova after more than 25 years of healthcare experience at Johnson & Johnson (J&J) where he most recently served as Group Chief Financial Officer, Medical Devices. While at J&J, Huston was pivotal in accelerating the growth for many of its divisions through focused strategies, calculated investments in innovation and streamlined productivity.
Huston held various other senior roles while at J&J, including: President of J&J’s Xian-Janssen Pharmaceuticals division in China; Vice President – Finance, Chief Financial Officer and Chief Operations Officer in J&J Pharmaceutical Research and Development; as well as Vice President – Finance and Chief Financial Officer at Ortho-McNeil Pharmaceuticals. Prior to this, he held senior financial roles at various J&J locations in the U.S., China, Belgium, Russia and Hungary.
A Certified Management Accountant, Huston holds a Bachelor of Science in finance with an emphasis in accounting from Pennsylvania State University.
Bryan Olin, PhD is the Senior Vice President, Clinical, Quality & Regulatory Affairs at LivaNova.
Dr. Olin joined Cyberonics in May 2009 as Vice President, Quality. In August 2009, he assumed additional responsibility for Clinical Affairs, and in April 2011, his responsibilities were expanded again to include Regulatory Affairs. With the 2015 merger between Cyberonics and Sorin, his responsibilities expanded to include corporate-wide responsibilities for the clinical, quality and regulatory affairs functions at LivaNova.
Prior to May 2009, Dr. Olin was employed at Zeltiq Aesthetics, Inc., a privately held medical technology company in the San Francisco area, where he served as Sr. Director, Quality Assurance since October 2007. Prior to Zeltiq Aesthetics, Dr. Olin was employed at the LifeScan and Cordis companies of Johnson & Johnson from 1999 to 2007, holding several positions of increasing responsibility in quality assurance, statistics and clinical data management. Dr. Olin began his career with Procter & Gamble in 1993 after obtaining his Ph.D. in Statistics from Iowa State University.
He currently serves on the board of directors for the Medical Devices Innovation Consortium (MDIC) and as an industry representative on the Advisory Committee for The National Patient-Centered Clinical Research Network (PCORnet).
David S. Wise is Chief Administrative Officer at LivaNova with oversight responsibility for Legal, Human Resources and Information Technology.
Previously, Wise served as Senior Vice President, Human Resources and Information Technology at LivaNova and Senior Vice President, Chief Administrative Officer and Secretary at Cyberonics. Wise joined Cyberonics in September 2003 as Vice President and General Counsel. He was appointed Secretary in November 2003 and assumed responsibility for Human Resources in June 2009. In April 2011, he was appointed Senior Vice President and Chief Administrative Officer, with responsibility for Legal, Human Resources, Information Technology and New Business Development.
From 1994 to 2003, he was employed in positions of increasing responsibility at Centerpulse USA, Inc. (formerly Sulzer Medica), a global medical devices company, where he served as Group Vice President and General Counsel.
Prior to Centerpulse, he spent 12 years in private practice focused on intellectual property and commercial litigation.